Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on MRNS. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $0.55 on Friday. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $10.50. The business’s fifty day moving average price is $0.46 and its two-hundred day moving average price is $0.88. The firm has a market capitalization of $30.32 million, a PE ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Suvretta Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the period. Franklin Resources Inc. grew its holdings in Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares during the period. abrdn plc grew its holdings in Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after acquiring an additional 1,578,329 shares during the period. GSA Capital Partners LLP grew its holdings in Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Marinus Pharmaceuticals by 266.1% during the fourth quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 354,393 shares during the period. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.